Background Myeloid sarcoma (MS) is a rare extra-medullary tumour of the myeloid lineage, which can be a difficult diagnosis to make. Case presentation We report the case of a 73-year-old male with a right-sided nasopharyngeal mass revealed on CT scan and MRI.
Introduction
A myeloid sarcoma is a tumor consisting of myeloblasts with or without maturation occurring in an anatomic site other than the bone marrow or peripheral blood [1] . The diagnosis is often difficult, especially when the disease occurs without any hematological bone marrow abnormality, and is based on morphological and immunohistochemical findings. The incidence of MS is not clearly known because of frequent misdiagnoses, but is reported in about 3 % of patients with acute myeloid leukemia (AML) [2] , the diagnosis of MS being established by necropsy in some patients [3] . MS may be observed at diagnosis or at the time of relapse [1, 4, 5] .
Case Presentation
We report the case of a patient diagnosed with a MS and a very unusual clinical presentation. A 73 year-old Caucasian man with no previous history, presented with a rightsided nasopharyngeal mass. A CT scan and an MRI of the nasopharynx revealed a mucosal thickening of the left maxillary sinus and filling of some right posterior ethmoidal cells (Fig. 1) . The PET-CT Scan depicted abnormal FDG uptake in the nasopharynx (SUV max 5.25) and the cervical lymph nodes (SUV max 4). The blood count revealed slight hyperleukocytosis (11 9 10 9 /L) with monocytosis (2.3 G/L) without any other abnormality. The monocytosis fluctuated between 0.5 and 1.4 G/L for several days with a peak at 2.3 G/L. At the same time the CRP level was elevated and ranged between 35 and 75 mg/L without any overt sign of infection or fever. A bone marrow aspiration showed a normal marrow without any significant abnormality including acute myeloid leukemia. No signs of dysplasia were noted on the peripheral blood and bone marrow smears. Cytogenetic analysis on the bone marrow was normal as well. Cerebrospinal fluid was acellular. A biopsy of the nasopharynx was done with biopsy imprints (touch preparations) for cytological examination. The histological examination showed malignant infiltration of medium to large-sized cells with an irregular nucleus, suggesting a high-grade lymphoma (Fig. 2, top) . Touch biopsy imprints stained with MGG ( Fig. 2, low) revealed a majority of atypical cells exhibiting a lymphoid appearance with a high nucleocytoplasmic ratio, loosely condensed chromatin, inconspicuous nucleoli and an irregular nuclear profile. After careful analysis, very fine coarse cytoplasmic granules within the malignant cells as well as very rare images of cytophagia were observed. However, the malignant cells did not express lymphoid markers (CD20, CD79a, CD23, CD3, CD5, CD4, CD8, CD57), but stained positively for myeloperoxidase and for CD15 (Fig. 2, low) . Flow cytometry of a tumor cell suspension obtained after gentle disruption of the biopsy specimen revealed a medium-sized clustered population of low granularity, expressing markers of myeloid assignment: CD13?, CD33?, CD117?, with positivity for HLA-DR antigen and negativity for immaturity marker CD34 (Fig. 3) . Fluorescence in situ hybridization (FISH) analysis of paraffin-embedded tumour slides did not identify either the t(8;21) translocation or MLL gene dissociation. The final diagnosis was a MS unusually involving the nasopharynx with no bone marrow disease.
The patient was treated with conventional induction AML therapy: a combination of Idarubicin (Zavedos) (12 mg/m 2 day 1 and 2) and Cytarabine (Cytosar) (200 mg/ m 2 day 1-day 7) followed by only one course of consolidation with Idarubicin (Zavedos) 12 mg/m 2 day 1 and Cytarabine (Cytosar) 1 g/m 2 /12 h day 1-day 5 due to a severe neutropenia and thrombocytopenia (grade 3-4) that appeared following the induction. The clinical outcome was favourable, the PET-CT Scan showed no abnormal FDG uptake, the bone marrow and blood count were normal except for a megakaryocytic hypoplasia. Eight months later, a new marrow aspiration was done in front of a persistent thrombocytopenia (grade 1-2) that was monitored and treated symptomatically at first. The bone marrow showed an excess of blasts (12 %) with monocytic differentiation associated with signs of dysgranulopoiesis. Bone marrow cytogenetic analysis revealed a t(3,21) (q26;q22) translocation (EVI1 and RUNX1 rearrangement demonstrated by FISH), that was not found on the initial bone marrow aspiration and tumour biopsy. A high-risk myelodysplastic syndrome was diagnosed and a 5-Azacitidine-treatment (Vidaza) regimen was started (75 mg/m 2 per day for 7 days every 28 days). After 4 cycles the patient had a cytological remission (medullar blasts less than 5 %) without cytogenetic remission. The cycles were pursued until September 2011 (22 cycles). In December 2011 another bone marrow examination evidenced an overt acute myeloblastic leukaemia with more than 30 % of blasts; the patient was enrolled in a phase I trial with the Etoposide derived drug (F14512). After 2 cycles there was no response with the persistence of peripheral blasts and thrombocytopenia; the treatment was stopped. The patient died from disease evolution later on.
Discussion
Myeloid sarcoma (MS) is a malignant extra-medullary tumor of myeloid immature cells that is rarely reported. It can occur de novo and is considered as the equivalent of a diagnosis of acute myeloid leukemia or in association with other myeloid disorders (mostly AML, myeloproliferative diseases especially CML and MDS) in many anatomical sites [1, 6] . A review was recently published of 17 cases with a MS of the head and neck region, mostly involving the oral cavity and none having a nasopharyngeal involvement [2] . The nasopharynx can be the site of a variety of neoplasms and hematolymphoid lesions such as nasopharyngeal carcinoma, N/K cell lymphoma, Castleman's disease and follicular dendritic cell sarcoma [7] [8] [9] . Few cases of MS in the nasopharynx were reported in the literature [6, 10] . The recognition of MS from these other lesions is of clinical importance. The appropriate therapy is often delayed because of a high misdiagnosis rate especially when the MS is poorly differentiated [11] . The morphology findings of myeloid sarcoma are myeloblasts with or without findings of promyelocytic or neutrophilic maturation [12] . When the initial MS site involves the lymphoid organs, a non-Hodgkin lymphoma is frequently initially suspected since lymphoma and MS may share morphologic similarities and expression of common leukocyte antigens like CD43 and CD45. The most reliable antigens reported in the literature that could be helpful for the diagnosis are:
• CD13 and CD68, markers of granular, monocytic and macrophagic cells The correct diagnosis can usually be established by having a detailed history, examination of peripheral blood/ bone marrow and immunohistochemical studies.
MS are more frequently observed with CBF (Core binding factor) AML: AML 2 with a t(8,21) translocation and usually a CD56-positive phenotype, and AML 4 with inversion of chromosome 16, or a translocation t (16, 16) [7, 11, 15, 16] . Some cases of promyelocytic sarcoma with a t(15;17) have also been reported [17, 18] . In the present case, the patient developed a high-risk myelodysplasia eight months after the diagnosis of a MS of the nasopharynx. Cytogenetic studies demonstrated a t(3;21) translocation involving EVI1 (on chromosome 3) and RUNX1 (on chromosome 21). Surprisingly, it was not detected at first neither on the nasopharyngeal tumour nor on the bone marrow analysis; either due to insufficient sensitivity of the FISH procedure or because of the secondary nature of the myelodysplasia. Indeed, hematologic malignancies associated with DNA-topoisomerase II targeted therapy are characterized by a relatively short latency period, and cytogenetic abnormalities in this setting involve mainly chromosome bands 11q23 (MLL) or 21 q22 (RUNX1) [19] . However, an eight months period of treatment, with lower dose than usual of anthracycline, because of a persistent thrombocytopenia, appears to be a very short latency and makes hardly probable the hypothesis of a treatment-related myelodysplasia.
No clear consensus or recommendation for the treatment exists in the literature. The prognosis seems more dismal than overt AML although it remains controversial [4, 15] .
Patients who present with MS with no bone marrow involvement could have a better prognosis than those with systemic involvement [20] . Based on the recent published studies and/or reviews, combination chemotherapy used in AML (induction followed by consolidation) in association with a local resection seems appropriate [4, 15] . High-dose chemotherapy followed by stem cell transplantation may be associated with a higher probability of survival or cure [14] . Local radiotherapy may also yield better local tumor control if residual disease persists or the tumor relapsed after initial chemotherapy [21, 22] .
In conclusion MS is a rarely identified disease when localized within the nasopharynx. A high index of suspicion is required for the diagnosis and MS should be considered in tumors of the nasopharynx especially those who are poorly differentiated and when the immunophenotype of the malignant hematological cells is not clearly in favor of a lymphoma.
